Suzan Pae, MD
Allergy & Immunology · Lincoln, NENPI 1811977580
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,664 of the $7,833 with a category attached, or 72.3%. 33 manufacturers reported payments, led by Consortium Of Independent Immunology Clinics, LLC at 27.4% of the total. Reporting peaked in 2024 at $2,737 and has fallen 53.7% since, to $1,267 in 2025. That places this record below the midpoint for allergy & immunology clinicians in NE, where the typical reported total is $7,833.
Across 313 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Consortium Of Independent Immunology Clinics, LLC$2K
- Sanofi$2K
- AstraZeneca$1K
- Amgen$331
- Takeda Pharmaceuticals U.S.A., Inc.$293
- Kaleo, Inc.$229
- plus $2K from 27 others
Across 2 payments — averaging $359.86 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$720
What the payments were for
- Consulting fees$2,14327%
- Food & beverage$5,66472%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Consortium Of Independent Immunology Clinics, LLC | 2 | $2,143 |
| Sanofi | 109 | $1,987 |
| AstraZeneca | 50 | $1,051 |
| Amgen(2 entities) | 18 | $331 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $293 |
| Kaleo, Inc. | 14 | $229 |
| CSL Behring | 10 | $216 |
| GSK | 13 | $183 |
| Novartis | 10 | $182 |
| Optinose US, Inc. | 10 | $171 |
| AbbVie | 8 | $141 |
| Octapharma USA, Inc. | 3 | $97 |
| Hospira, Inc. | 5 | $85 |
| Regeneron Healthcare Solutions, Inc. | 4 | $83 |
| Shire North American Group Inc | 4 | $80 |
| Boehringer Ingelheim | 4 | $69 |
| Genentech USA, Inc. | 5 | $57 |
| Biocryst US Sales Co., LLC | 4 | $51 |
| Aimmune Therapeutics, Inc. | 3 | $50 |
| Pfizer | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Blueprint Medicines Corporation | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| LEO Pharma Inc. | 1 | $31 |
| Covis Pharma GmbH | 2 | $28 |
| Pharming Healthcare, Inc. | 2 | $24 |
| Incyte Corporation | 1 | $24 |
| Merck | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Grifols USA, LLC | 1 | $14 |
| Encore Dermatology Inc. | 1 | $13 |
| Biocryst Pharmaceuticals, Inc. | 1 | $12 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$129
How this compares
$7,833 in reported general payments places this provider in the 50th percentile of 21 allergy & immunology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 38 | $159,700 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 15 | $61,909 |
| Dupixent SyringeDupilumab | 13 | $57,382 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $24,271 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,971 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $3,997 |
| Azelastine Hcl | 125 | $3,264 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $3,086 |
| Epinephrine | 14 | $2,333 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,276 |
| Ipratropium Bromide | 51 | $1,824 |
| Fluticasone Propionate | 145 | $1,819 |
| Montelukast Sodium | 78 | $622 |
| Mometasone Furoate | 15 | $368 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $216 | $61,90915 claims |
| GSKTrelegy Ellipta | $183 | $24,27134 claims |
| Boehringer IngelheimSpiriva Respimat | $69 | $5,97111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 21 allergy & immunology providers in Nebraska.
Other allergy & immunology in Lincoln
- Robert SzalewskiLincoln$78K
- Petra Jonsson RazdanLincoln$7K
- Hannah NeuhausLincoln$3K
- Kevin MurphyBoys Town$1.1M
- James TracyOmaha$104K
- Linda FordBellevue$78K
- Roger KobayashiOmaha$45K
- Mitchell PitlickOmaha$26K
- James FriedlanderOmaha$22K
- Brett KettelhutOmaha$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.